Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19+ and CD 22+ B-ALL”

3 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 3 of 3 results

Early research (Phase 1)Study completedNCT00889408
What this trial is testing

DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma

Who this might be right for
LeukemiaLymphoma
Masonic Cancer Center, University of Minnesota 25
Very early researchUnknownNCT05225831
What this trial is testing

Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
CD19+ and CD 22+ B-ALL
Hebei Senlang Biotechnology Inc., Ltd. 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07162571
What this trial is testing

This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

Who this might be right for
Acute Lymphobkastic LeukemiaB Cell Lymphoma
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology 17